Clinical Trials Directory

Trials / Unknown

UnknownNCT03914820

Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.

Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. CHECK STUDY

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
330 (estimated)
Sponsor
Mario Negri Institute for Pharmacological Research · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a phase III randomized, multicenter study with two different arm: * experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin * comparator: standard surgery Adjuvant treatment after surgery is mandatory except for documented cases of non-eligibility. Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the total resection of tumour will be reached and will use a stratification procedure based on center

Detailed description

This is a phase III randomized, multicenter study with two different arm: * experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin * comparator: standard surgery Adjuvant treatment after surgery is mandatory except for documented cases of non-eligibility. Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the total resection of tumour will be reached and will use a stratification procedure based on center The HIPEC CO2 regimen will be as reported below: mitomycin: (total dose of 35 mg/mq, physiologic solution 0.9%) administrated 50% at time 0 from start of HIPEC CO2 treatment (17.5 mg/mq), 25% (8.8 mg/mq) after 30 minutes and the last dose 25% after 60 minutes. Recommended temperature for HIPEC treatment is 41-42 °C for 90 minutes. Adjuvant treatment consists of a 6 months chemotherapy after surgery. It is possible to choose between Oxaliplatin, Capecitabine (XELOX) or Oxaliplatin, Fluorouracil, Leucovorin (FOLFOX-4) Patients affected by CRC at high risk of developing peritoneal carcinomatosis will be randomized in the study.

Conditions

Interventions

TypeNameDescription
PROCEDUREHIPEC CO2 surgeryProphylactic surgery plus HIPEC CO2 performed with mitomycin
PROCEDUREStandard surgeryStandard surgery without HIPEC CO2
DRUGMitomycinProphylactic surgery plus HIPEC CO2 performed with mitomycin

Timeline

Start date
2020-06-19
Primary completion
2025-06-01
Completion
2025-06-01
First posted
2019-04-16
Last updated
2023-10-27

Locations

16 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT03914820. Inclusion in this directory is not an endorsement.